The Relitect technology is an electronic platform capable of detecting incredibly low levels of multiple biomarkers in real sample matrices.

The platform is based upon the following:

  • Low-cost semiconductor devices with arrays of gold electrodes
  • Self-assembled polymer coatings to allow for functionalization of the electrodes
  • Subsequent attachment of specific bio-recognition molecules (e.g. antibodies) to detect the biomarkers of interest
  • A novel and patented electronic approach for detection of any specific binding events in real-time without the need for secondary recognition events (i.e. ‘label-free’)

How it works

Wälti et al at Leeds University have developed a detection technology for binding events based upon changes in the electrochemical impedance that occur when binding events take place on an electrode surface.

The binding events produce a change in the phase of the impedance response, which can be measured directly.


Sample Results

Detection of IL8 in animal serum
90 fg/ml sensitivity
Time to result = 5 minutes
Data and graph extracted from Sharma et al, 2015 (Leeds University)


Key Benefits

Compared to current ‘on-the-market’ technologies, the Relitect technology has several key benefits:

  • increased sensitivity
  • high multiplexing capability
  • lack of matrix effects
  • reduced cost per analyte test
  • reduced analysis time and actual ‘real-time’ analysis
  • reduced waste chemical disposal
  • because it is ‘label-free’ there will be reduced sample interference when multi-plexing due to there being no possibility of labelled reagent cross-talk

Key Publications

Related papers:

  • Evans et al (2008) Electrical Protein Detection In Cell Lysate Using High Density Peptide-Aptamer Microarays
  • Raina et al (2015) Antibody mimetic label-free biosensors
  • Sharma et al (2015) Label-free electrochemical impedance biosensor to detect human Interleukin-8 in serum with femto-molar sensitivity (submitted for publication)